Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 80

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 80
---
 Net Sales Price). Under the SKNY-1 Licensing Agreement, SKNY is permitted to license SKNY-1 to third parties for an 8% fee on all revenue earned from such sublicensee. The SKNY-1 Licensing Agreement expires upon the expiration of the later of the SKNY-1 patent and the date of expiration of the last strategic partnership/sublicensing agreement covering SKNY-1. SKNY may terminate the SKNY-1 Licensing Agreement at any time upon thirty (30) days prior written notice to MIRALOGX. The full text of the SKNY-1 Licensing Agreement is attached as Annex E to this proxy statement.

Competitors for Weight Loss Products

There are several potential pharmaceutical companies that we deem as competitors actively developing new weight loss drugs. These companies are working on innovative therapies, primarily focusing on GLP-1 agonists and other mechanisms to address obesity, a field experiencing explosive growth. These companies may have products that are more advanced in their development and FDA-process than SKNY-1 or have more resources than SKNY. These companies include:

| ● | Eli                                                                                                                                          
 Lilly & Company (NYSE:LLY) – LLY has developed Zepbound (Tirzepatide), which was approved by the FDA in 2023. Zepbound                       
 is a dual GLP-1/GIP agonist, achieving up to 20% weight loss in trials. LLY offers vials measuring 2.5 mg for $349 per month, 5 mg           
 for $499 per month, 7.5 mg for $599 per month, and 10 mg for $699/month. Pen pricing is 2.5 mg/0.5 mL subcutaneous solutions for             
 around $374 for 2 mL. Additionally, LLY has also developed orforglipron, an oral GLP-1 agonist in Phase 3 trials, showing a 13.5%            
 weight loss in early data, potentially a game-changer due to its non-injectable form, and retatrutide, a triple agonist (GLP-1/GIP/glucagon) 
 in Phase 3, with trials indicating up to a 24% weight loss, one of the highest efficacy rates seen so far.                                   |
| ● | Novo                                                                                                                                         
 Nordisk A/S (NYSE: NVO) – NVO is developing Wegovy (semaglutide), an FDA-approved GLP-1 agonist with an average weight loss